Bioactivity:

Pilaralisib is an orally available small molecule that selectively inhibits the activity of phosphoinositide-3 kinase (PI3K). Pilaralisib has been used in trials studying the treatment of Cancer, Lymphoma, Solid Tumors, Glioblastoma, and Breast Cancer, am

CAS nr:

934526-89-3

Purity:

98%

Molecular Weight:

541,02

SMILES:

C(=O)(C(C)(C)N)Nc1cc(ccc1)S(=O)(=O)Nc1nc2c(nc1Nc1c(ccc(c1)OC)Cl)cccc2

Formula:

C25H25ClN6O4S

Pathway:

PI3K/Akt/mTOR signaling

Target:

PI3K